To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. The gene discussed is IL33; the disease is eosinophilic granulomatosis with polyangiitis.